Niveles de anticuerpos bactericidas frente a meningococo C tras la vacunación de niños de 2 a 6 años de edad en Andalucía

Delgado Torralbo, Elena; Vazquez Moreno, Julio; García León, Javier; Martínez Navarro, Ferrán; Berrón Morato, Sonsoles; Bernal González, M. Luisa; González Enríquez, Jesús; Mayoral Cortés, José María; Rubin Gómez, M. Angeles; Méndez Martínez, Camila; Cortés Majó, Margarita; Chaves Caballero, Mónica.
Rev. esp. salud pública ; 74(4): 433-444, jul. 2000.
Artículo en Es | IBECS (España) | ID: ibc-9695

Documentos relacionados

  1. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.
  2. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
  3. Re-randomization tests as sensitivity analyses to confirm immunological noninferiority of an investigational vaccine: Case study.
  4. [Immunogenicity of group A+C meningococcal polysaccharide conjugate vaccine in infants: A phase Ⅲ clinical trial study].
  5. Good News and Bad News - 4CMenB Vaccine for Group B <i>Neisseria meningitidis</i>.
  6. Evolution of Sequence Type 4821 Clonal Complex Hyperinvasive and Quinolone-Resistant Meningococci.
  7. Investigation of bioluminescence-based assays for determination of kinetic parameters for the bifunctional Neisseria meningitidis serogroup W capsule polymerase.
  8. Stability of lyophilized Meningococcal A conjugate vaccine, (MenAfriVac&#8482;) at elevated temperatures to support controlled temperature chain (CTC) claim.
  9. Nurses' preferences regarding MenACWY conjugate vaccines attributes: a discrete choice experiment in Spain.
  10. Informing the use of a supplementary immunisation programme for the management of a community cluster of invasive meningococcal disease, Yorkshire, 2022.